iPSC-derived Limbal Stem Cell Therapy
Limbal Stem Cell Deficiency (LSCD) leading to corneal blindness
Pre-clinicalActive
Key Facts
Indication
Limbal Stem Cell Deficiency (LSCD) leading to corneal blindness
Phase
Pre-clinical
Status
Active
Company
About StemSight
StemSight, founded in 2018 and based in Helsinki, is a preclinical-stage biotechnology company focused on developing regenerative cell therapies for corneal blindness. The company leverages its expertise in differentiating human pluripotent stem cells into ocular cell types and combining them with biomaterials to create advanced therapeutic solutions. With a seasoned leadership team and recognition as one of Europe's most innovative life science startups, StemSight is preparing for a Series A financing round to advance its lead program. The company targets a large global patient population suffering from limbal stem cell deficiency and other corneal disorders.
View full company profile